Focused On-demand Library for Transcription factor A, mitochondrial

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q00059

UPID:

TFAM_HUMAN

Alternative names:

Mitochondrial transcription factor 1; Transcription factor 6; Transcription factor 6-like 2

Alternative UPACC:

Q00059; A8MRB2; A9QXC6; B5BU05; Q5U0C6

Background:

Transcription factor A, mitochondrial (TFAM), also known as Mitochondrial transcription factor 1, plays a pivotal role in mitochondrial DNA maintenance, transcription regulation, and compaction. It binds to the mitochondrial light strand promoter, facilitating transcription initiation by unwinding DNA and bending it into a U-turn shape. This action is crucial for the accurate and efficient recognition by the mitochondrial RNA polymerase, alongside its involvement in the mitochondrial transcription initiation complex.

Therapeutic significance:

TFAM's critical function in mitochondrial DNA maintenance links it to Mitochondrial DNA depletion syndrome 15, hepatocerebral type, a severe disorder with rapid progression to liver failure. Understanding the role of TFAM could open doors to potential therapeutic strategies for this and related mitochondrial diseases.